Fig. 4: Effect of dapagliflozin on clinical outcomes across the range of NT-proBNP. | Nature Medicine

Fig. 4: Effect of dapagliflozin on clinical outcomes across the range of NT-proBNP.

From: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

Fig. 4

a–f, Effect of dapagliflozin on: death from CV causes (a); death from all causes (b); the total number of hospital admissions for HF (c); time to first hospital admission for HF (d); death from CV causes, MI or stroke (e); and death from CV causes or hospital admission for HF (f), according to baseline NT-proBNP level. The horizontal blue line shows the continuous HR across the range of NT-proBNP levels at baseline and the shaded area around this line represents the 95% CI from Cox’s model. The overall effect of treatment in the pooled population is shown in each panel as an HR (95% CI) with the two-sided P value for Wald’s test of interaction between treatment and NT-proBNP level from Cox’s model. No adjustment for multiple comparisons was made. aRestricted cubic spline and interaction P value derived from LWYY model for total HF hospitalization.

Back to article page